Land: Kanada
Sprache: Englisch
Quelle: Health Canada
DONEPEZIL HYDROCHLORIDE (DONEPEZIL HYDROCHLORIDE MONOHYDRATE)
APOTEX INC
N06DA02
DONEPEZIL
5MG
TABLET
DONEPEZIL HYDROCHLORIDE (DONEPEZIL HYDROCHLORIDE MONOHYDRATE) 5MG
ORAL
30/100/500
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0131548001; AHFS:
APPROVED
2013-12-24
_APO-DONEPEZIL Tablets Product Monograph_ _Page 1 of 46_ PRODUCT MONOGRAPH PR APO-DONEPEZIL Donepezil Hydrochloride Tablets Tablets, 5 mg and 10 mg (as donepezil hydrochloride monohydrate) USP Cholinesterase Inhibitor APOTEX INC. Date of Revision: 150 Signet Drive January 17, 2023 Weston, Ontario M9L 1T9 Submission Control No.: 266376 _APO-DONEPEZIL Tablets Product Monograph_ _Page 2 of 46_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................... 3 SUMMARY PRODUCT INFORMATION......................................................................... 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 3 WARNINGS AND PRECAUTIONS.................................................................................. 3 ADVERSE REACTIONS .................................................................................................. 8 DRUG INTERACTIONS ................................................................................................. 15 DOSAGE AND ADMINISTRATION .............................................................................. 16 OVERDOSAGE .............................................................................................................. 17 ACTION AND CLINICAL PHARMACOLOGY ............................................................. 18 STORAGE AND STABILITY ......................................................................................... 20 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................... 20 PART II: SCIENTIFIC INFORMATION ........................................................................ 21 PHARMACEUTICAL INFORMATION .......................................................................... 21 CLINICAL TRIALS ................................................................................................ Lesen Sie das vollständige Dokument